Drug Trial Radar · NCT03645980
DKN-01 Inhibition in Advanced Liver Cancer
Last checked: Nov 19, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Planned (sponsor's estimate)
Start
Oct 10, 2018
Primary completion
Aug 31, 2021
Study completion Aug 31, 2022
Sponsor
- Lead sponsor
- Johannes Gutenberg University MainzAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Leap Therapeutics, Inc.
- First posted
- Aug 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a prospective, open label, single arm oncological phase I/II trial in patients with hepatocellular carcinoma and WNT signaling alterations. The trial consists of two parts: Part A is a phase I study investigating the safety of DKN-01 administered as mono- as well as combination therapy with sorafenib in a 2 step dose escalation.Part B is a phase II study to investigate the anti-tumor activity and safety of DKN-01 in patients with advanced HCC. DKN-01 is administered at the recommend phase II dose (RP2D) for monotherapy and at the recommend phase II dose for combination therapy established in Part A.
Conditions
- Hepatocellular Carcinoma
Interventions
DKN-01 300 mgDrug
DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
DKN-01 600 mgDrug
DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
SorafenibDrug
For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Adverse EventsTime frame: assessment period is 2 cycles for monotherapy (each cycle is 28 days)
- Phase I: Adverse EventsTime frame: assessment period is 2 cycles for combination therapy (each cycle is 28 days)
- Phase II: Time to progression (TTP2)Time frame: time from the first DKN-01 intake until PD2, assessed up to 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Köln
Cologne, Germany · Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Med. Hochschule Hannover
Hanover, Germany · Recruiting
Universitätsklinikum Schleswig Holstein Campus Lübeck
Lübeck, Germany · Recruiting
Universitätsmedizin Mainz, I. Med. Klinik und Poliklinik
Mainz, Germany · Recruiting
II. Medizinische Universitätsklinik Gastroenterologie, Hepatologie, Infektiologie
Mannheim, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.